Status:
COMPLETED
A Sleep Lab Trial to Investigate the Efficacy and Safety of Transdermal Rotigotine in Subjects With Idiopathic Restless Legs Syndrome
Lead Sponsor:
UCB Pharma
Conditions:
Restless Legs Syndrome
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
The objective of this trial is to demonstrate that rotigotine (SPM 936) is effective in subjects with idiopathic RLS based on the PLMI (Periodic Limb Movements Index)(PLMs/total time in bed) as measur...
Eligibility Criteria
Inclusion
- Idiopathic RLS
Exclusion
- secondary RLS
- history of sleep disturbances
- symptomatic orthostatic hypotension
Key Trial Info
Start Date :
November 1 2005
Trial Type :
INTERVENTIONAL
End Date :
July 1 2006
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00275236
Start Date
November 1 2005
End Date
July 1 2006
Last Update
September 25 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Schwarz BioSciences
Monheim, Germany